Divalproex Sodium Tablet, Delayed Release
Product Images NDC 70518-3683

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 70518-3683). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
This is a medication called Divalproex Sodium. The tablet is delayed-release and has a strength of 125 mg. The quantity is 30 tablets and it is available only on prescription. The NDC number is 70518-3682-00 and the manufacturer is Rising Pharma, Inc. It is advised to keep this medication out of the reach of children and to see the package insert for directions of use. The medication should be stored between 20-25°C (88-77°F) with excursions permitted o 15-30°C (59-86°F) [See USP]. It has been repackaged by RemedyRepack Inc. in Indiana, PA.*
FDA Label Image

Figure 1 (Divalproex Fig1)

Figure 1 (Divalproex Fig1)
The text describes a figure (Figure 1) that contains information about two studies, Study 1 and Study 2. The studies may relate to years and WIRS. The text also includes abbreviations, namely PBO, DVPX, and P80, which may have been used to represent various elements in the studies. Lastly, the text indicates that a statistical analysis was performed, and there was a significant difference between the placebo (PBO) and divalproex sodium delayed-release tablets (DVPX) treatments, denoted by *p<0.05.*
FDA Label Image

Figure 2 (Divalproex Fig2)

Figure 2 (Divalproex Fig2)
FDA Label Image

Figure 3 (Divalproex Fig3)

Figure 3 (Divalproex Fig3)
The text is a chart showing the impact of dosage on the reduction of "InCPS Rate", with the x- axis labeled "High Dose" to "Low Dose" and the y-axis showing "% of Patients". The chart displays the percentage of patients with improvement, no change or worsening based on the dose.*
FDA Label Image

Figure 4 (Divalproex Fig4)

Figure 4 (Divalproex Fig4)
The text describes the mean 4-week migraine rates for two studies involving the use of placebo and divalproex sodium delayed-release tablets. Study 1 had a mean dose of 1,087 mg/day while study 2 had a dose of either 500 or 1,000 mg/day of divalproex sodium delayed-release tablets.*
FDA Label Image

Chemical Structure (Divalproex Str)

Chemical Structure (Divalproex Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.